Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-173-1 | CAS number: -
Specific IgE antibodies against the respective diisocyanate were: MDI, 12/46 (26.1%); TDI, 6/29 (20.7%); HDI 5/37 (13.5%). As compared to the,'normal group' (group 6), no significant differences in the titres of specific IgG and IgG4 antibodies could be found, either for the groups of test persons exposed to MDI and TDI (groups 2 + 3), or for the groups of MDI and TDI asthmatics (group 1) and the two groups of miners (groups 4 + 5). HDI-exposed atopic persons (group 2), as well as exposed non-atopic persons (group 3) and HDI-asthmatics (group 1), showed significantly higher titres of specific IgG and IgG4 antibodies as compared to the normal group (group 6). The non-specific bronchial hyperreactivity found in Group 1 was: MDI 38/46 (82.6%); TDI, 24/29 (82.8%); HDI, 37/37 (100%); controls, 11/52 (21.15%)
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again